Regulation and Function of the PD-L1 Checkpoint

被引：1787

作者：

Sun, Chong ^{[1
]}

Mezzadra, Riccardo ^{[1
]}

Schumacher, Ton N. ^{[1
]}

机构：

[1] Netherlands Canc Inst, Oncode Inst, Div Mol Oncol & Immunol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands

来源：

IMMUNITY | 2018年 / 48卷 / 03期

关键词：

SQUAMOUS-CELL CARCINOMA; CISPLATIN-INELIGIBLE PATIENTS; TUMOR-ASSOCIATED MACROPHAGES; CLASSICAL HODGKIN LYMPHOMA; PROGRAMMED DEATH LIGAND-1; INDUCED UP-REGULATION; CD8(+) T-CELLS; IFN-GAMMA; B7-H1; EXPRESSION; DENDRITIC CELLS;

D O I：

10.1016/j.immuni.2018.03.014

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor immunity by counteracting T cell-activating signals. Antibody-based PD-1-PD-L1 inhibitors can induce durable tumor remissions in patients with diverse advanced cancers, and thus expression of PD-L1 on tumor cells and other cells in the tumor microenviroment is of major clinical relevance. Here we review the roles of the PD-1-PD-L1 axis in cancer, focusing on recent findings on the mechanisms that regulate PD-L1 expression at the transcriptional, posttranscriptional, and protein level. We place this knowledge in the context of observations in the clinic and discuss how it may inform the design of more precise and effective cancer immune checkpoint therapies.

引用

页码：434 / 452

页数：19

共 205 条

[1] Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes [J].

Agata, Y ;

Kawasaki, A ;

Nishimura, H ;

Ishida, Y ;

Tsubata, T ;

Yagita, H ;

Honjo, T .

INTERNATIONAL IMMUNOLOGY, 1996, 8 (05) :765-772

[2] Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors [J].

Akbay, Esra A. ;

Koyama, Shohei ;

Carretero, Julian ;

Altabef, Abigail ;

Tchaicha, Jeremy H. ;

Christensen, Camilla L. ;

Mikse, Oliver R. ;

Cherniack, Andrew D. ;

Beauchamp, Ellen M. ;

Pugh, Trevor J. ;

Wilkerson, Matthew D. ;

Fecci, Peter E. ;

Butaney, Mohit ;

Reibel, Jacob B. ;

Soucheray, Margaret ;

Cohoon, Travis J. ;

Janne, Pasi A. ;

Meyerson, Matthew ;

Hayes, D. Neil ;

Shapiro, Geoffrey I. ;

Shimamura, Takeshi ;

Sholl, Lynette M. ;

Rodig, Scott J. ;

Freeman, Gordon J. ;

Hammerman, Peter S. ;

Dranoff, Glenn ;

Wong, Kwok-Kin .

CANCER DISCOVERY, 2013, 3 (12) :1355-1363

[3]

[Anonymous], J CLIN ONCOL

[4] The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice [J].

Ansari, MJI ;

Salama, AD ;

Chitnis, T ;

Smith, RN ;

Yagita, H ;

Akiba, H ;

Yamazaki, T ;

Azuma, M ;

Iwai, H ;

Khoury, SJ ;

Auchincloss, H ;

Sayegh, MH .

JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (01) :63-69

[5] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].

Ansell, Stephen M. ;

Lesokhin, Alexander M. ;

Borrello, Ivan ;

Halwani, Ahmad ;

Scott, Emma C. ;

Gutierrez, Martin ;

Schuster, Stephen J. ;

Millenson, Michael M. ;

Cattry, Deepika ;

Freeman, Gordon J. ;

Rodig, Scott J. ;

Chapuy, Bjoern ;

Ligon, Azra H. ;

Zhu, Lili ;

Grosso, Joseph F. ;

Kim, Su Young ;

Timmerman, John M. ;

Shipp, Margaret A. ;

Armand, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319

[6] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[7] Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure [J].

Armand, Philippe ;

Shipp, Margaret A. ;

Ribrag, Vincent ;

Michot, Jean-Marie ;

Zinzani, Pier Luigi ;

Kuruvilla, John ;

Snyder, Ellen S. ;

Ricart, Alejandro D. ;

Balakumaran, Arun ;

Rose, Shelonitda ;

Moskowitz, Craig H. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (31) :3733-+

[8] Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma [J].

Atefi, Mohammad ;

Avramis, Earl ;

Lassen, Amanda ;

Wong, Deborah J. L. ;

Robert, Lidia ;

Foulad, David ;

Cerniglia, Michael ;

Titz, Bjoern ;

Chodon, Thinle ;

Graeber, Thomas G. ;

Comin-Anduix, Begonya ;

Ribas, Antoni .

CLINICAL CANCER RESEARCH, 2014, 20 (13) :3446-3457

[9] PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma [J].

Atsaves, V. ;

Tsesmetzis, N. ;

Chioureas, D. ;

Kis, L. ;

Leventaki, V. ;

Drakos, E. ;

Panaretakis, T. ;

Grander, D. ;

Medeiros, L. J. ;

Young, K. H. ;

Rassidakis, G. Z. .

LEUKEMIA, 2017, 31 (07) :1633-1637

[10] PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p [J].

Audrito, Valentina ;

Serra, Sara ;

Stingi, Aureliano ;

Orso, Francesca ;

Gaudino, Federica ;

Bologna, Cinzia ;

Neri, Francesco ;

Garaffo, Giulia ;

Nassini, Romina ;

Baroni, Gianna ;

Rulli, Eliana ;

Massi, Daniela ;

Oliviero, Salvatore ;

Piva, Roberto ;

Taverna, Daniela ;

Mandala, Mario ;

Deaglio, Silvia .

ONCOTARGET, 2017, 8 (09) :15894-15911

← 1 2 3 4 5 6 7 8 9 10 →